In this scenario of rapid and interesting changes, menin inhibitors represent a novel class of drugs that have shown promising results in histone-lysine N-methyltransferase 2A (KMT2A)-rearranged (KMT2Ar) and in NPM1-mutated (NPM1mut) acute leukemias [1,2]. This evidence concerns the gene MEN1 and acute leukemia.